Aerocrine Releases Update on Insurance Coverage of FeNO Test in US.
Proquest LLC |
According to a release,
The new
Insurance companies typically review their medical policies on an annual basis or whenever substantially new clinical information becomes available. Currently, seven of the US's top 12 insurers provide coverage and reimbursement for this test. During the first quarter;
FeNO testing is a two minute, objective, point-of-care breath test that can be used to identify patients with allergic airway inflammation. Airway inflammation is recognized as the underlying cause of asthma. Using routine FeNO testing to guide therapy, particularly inhaled corticosteroid therapy, for asthma patients has been shown to reduce asthma exacerbations up to 50 percent.
"FeNO is an important addition to the management of many patients with asthma. It allows the presence of steroid responsive airway inflammation to be identified. FeNO testing helps clinicians prescribe the optimal medications and doses for their asthma patients which can improve patient outcomes," said Dr.
((Comments on this story may be sent to [email protected]))
Copyright: | (c) 2014 ProQuest Information and Learning Company; All Rights Reserved. |
Wordcount: | 529 |
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News